518 related articles for article (PubMed ID: 12452205)
21. [New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences].
de Weck A; Sanz ML; Gamboa P
Bull Acad Natl Med; 2005 Jun; 189(6):1201-18; discussion 1218-20. PubMed ID: 16433444
[TBL] [Abstract][Full Text] [Related]
22. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
[TBL] [Abstract][Full Text] [Related]
23. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs.
Campo P; Ayuso P; Salas M; Plaza MC; Cornejo-García JA; Doña I; Torres MJ; Blanca-López N; Canto G; Guéant JL; Sanak M; Blanca M
Allergy; 2013 Aug; 68(8):1001-7. PubMed ID: 23889565
[TBL] [Abstract][Full Text] [Related]
24. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance.
Bavbek S; Celik G; Ediger D; Mungan D; Demirel YS; Misirligil Z
J Asthma; 1999 Dec; 36(8):657-63. PubMed ID: 10609620
[TBL] [Abstract][Full Text] [Related]
25. A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial.
Sommer DD; Rotenberg BW; Sowerby LJ; Lee JM; Janjua A; Witterick IJ; Monteiro E; Gupta MK; Au M; Nayan S
Int Forum Allergy Rhinol; 2016 Apr; 6(4):385-91. PubMed ID: 26751262
[TBL] [Abstract][Full Text] [Related]
26. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization.
White AA; Stevenson DD
Semin Respir Crit Care Med; 2012 Dec; 33(6):588-94. PubMed ID: 23047310
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders.
Asero R
Ann Allergy Asthma Immunol; 1999 Jun; 82(6):554-8. PubMed ID: 10400483
[TBL] [Abstract][Full Text] [Related]
28. Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.
Walters KM; Waldram JD; Woessner KM; White AA
Am J Rhinol Allergy; 2018 Jul; 32(4):280-286. PubMed ID: 29682983
[TBL] [Abstract][Full Text] [Related]
29. Aspirin-exacerbated respiratory disease: clinical disease and diagnosis.
Bochenek G; Niżankowska-Mogilnicka E
Immunol Allergy Clin North Am; 2013 May; 33(2):147-61. PubMed ID: 23639705
[TBL] [Abstract][Full Text] [Related]
30. Current complications and treatment of aspirin-exacerbated respiratory disease.
Cook KA; Stevenson DD
Expert Rev Respir Med; 2016 Dec; 10(12):1305-1316. PubMed ID: 27817219
[TBL] [Abstract][Full Text] [Related]
31. Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.
Valero A; Sánchez-López J; Bartra J; Serrano C; Muñoz-Cano R; Roca J; Picado C
Int Arch Allergy Immunol; 2011; 156(2):221-3. PubMed ID: 21597303
[TBL] [Abstract][Full Text] [Related]
32. The prevalence of aspirin hypersensitivity in patients with nasal polyposis and contributing factors.
Bavbek S; Dursun B; Dursun E; Korkmaz H; Sertkaya Karasoy D
Am J Rhinol Allergy; 2011; 25(6):411-5. PubMed ID: 22185746
[TBL] [Abstract][Full Text] [Related]
33. Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.
West PM; Fernández C
Ann Pharmacother; 2003 Oct; 37(10):1497-501. PubMed ID: 14519044
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma.
Stankovic KM; Goldsztein H; Reh DD; Platt MP; Metson R
Laryngoscope; 2008 May; 118(5):881-9. PubMed ID: 18391768
[TBL] [Abstract][Full Text] [Related]
35. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.
Berges-Gimeno MP; Simon RA; Stevenson DD
Clin Exp Allergy; 2002 Oct; 32(10):1491-6. PubMed ID: 12372130
[TBL] [Abstract][Full Text] [Related]
36. Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
Adame MJ; Raji M; Shan Y; Zhang Y; Kuo YF; Tripple JW
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3445-3453.e6. PubMed ID: 37468040
[TBL] [Abstract][Full Text] [Related]
37. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.
Bochenek G; Kuschill-Dziurda J; Szafraniec K; Plutecka H; Szczeklik A; Nizankowska-Mogilnicka E
J Allergy Clin Immunol; 2014 Jan; 133(1):98-103.e1-6. PubMed ID: 23993879
[TBL] [Abstract][Full Text] [Related]
38. Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents.
Ertoy Karagol HI; Yilmaz O; Topal E; Ceylan A; Bakirtas A
Int Forum Allergy Rhinol; 2015 May; 5(5):392-8. PubMed ID: 25755210
[TBL] [Abstract][Full Text] [Related]
39. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
Shaker M; Lobb A; Jenkins P; O'Rourke D; Takemoto SK; Sheth S; Burroughs T; Dykewicz MS
J Allergy Clin Immunol; 2008 Jan; 121(1):81-7. PubMed ID: 17716716
[TBL] [Abstract][Full Text] [Related]
40. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
Wang XS; Wu AY; Leung PS; Lau HY
Allergy; 2007 Jun; 62(6):620-7. PubMed ID: 17508965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
